Redwood Investments LLC purchased a new position in Glaukos Corporation (NYSE:GKOS) during the second quarter, according to its most recent disclosure with the SEC. The fund purchased 162,902 shares of the medical instruments supplier’s stock, valued at approximately $6,756,000. Redwood Investments LLC owned about 0.48% of Glaukos Corporation as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Teachers Advisors LLC increased its position in shares of Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after buying an additional 1,506 shares during the period. Bank of Montreal Can bought a new position in shares of Glaukos Corporation during the first quarter valued at $3,196,000. Nationwide Fund Advisors increased its position in shares of Glaukos Corporation by 749.3% in the first quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock valued at $4,571,000 after buying an additional 78,610 shares during the period. DUPONT CAPITAL MANAGEMENT Corp bought a new position in shares of Glaukos Corporation during the first quarter valued at $776,000. Finally, Wells Fargo & Company MN increased its position in shares of Glaukos Corporation by 73.2% in the first quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock valued at $59,332,000 after buying an additional 488,730 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Shares of Glaukos Corporation (NYSE GKOS) opened at 37.12 on Tuesday. The company has a 50 day moving average price of $39.53 and a 200-day moving average price of $43.16. Glaukos Corporation has a 1-year low of $28.26 and a 1-year high of $52.49. The stock’s market capitalization is $1.28 billion.

TRADEMARK VIOLATION WARNING: “Redwood Investments LLC Purchases Shares of 162,902 Glaukos Corporation (GKOS)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/22/redwood-investments-llc-purchases-shares-of-162902-glaukos-corporation-gkos.html.

Several research analysts have weighed in on GKOS shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $56.00 target price on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Stephens upgraded Glaukos Corporation from an “equal weight” rating to an “overweight” rating in a research note on Monday, May 8th. Zacks Investment Research upgraded Glaukos Corporation from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Friday, July 14th. BidaskClub downgraded Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Thursday, May 4th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $52.33.

In other news, Director Orbimed Advisors Llc sold 325,000 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 16.40% of the stock is owned by corporate insiders.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.